Stifel Initiates Coverage On Eupraxia Pharmaceuticals with Buy Rating, Announces Price Target of $25
Benzinga Newsdesk 5 months ago
NewsPrice TargetInitiationAnalyst Ratings
Stifel analyst Annabel Samimy initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Buy rating and announces Price Target of $25.
Stifel analyst Annabel Samimy initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Buy rating and announces Price Target of $25.